MiniMed Group, Inc.

What does MiniMed Group own?
MiniMed Group owns the MiniMed insulin pump, CGM, and smart pen product lines, including the 780G system, Flex pump, Simplera Sync sensor, and InPen. It is a single-brand company.

Is MiniMed publicly traded?
Yes. MiniMed Group trades on the Nasdaq under ticker MMED. It priced its IPO in March 2026 and became fully independent from Medtronic in October 2026.

Who founded MiniMed?
Biomedical entrepreneur Alfred E. Mann founded MiniMed in 1983 to commercialize the insulin pump. Medtronic acquired the company in 2001 for roughly $3.7 billion.

Where is MiniMed headquartered?
MiniMed Group is headquartered in Northridge, California, where the business has been based since its founding.

Does Medtronic still own MiniMed?
No. Medtronic completed the separation on October 15, 2026, exchanging its entire remaining stake of about 90% with shareholders in a split-off. MiniMed is now fully independent.

How many brands does MiniMed own?
MiniMed operates as a single-brand company. All pumps, sensors, pens, and software are sold under the MiniMed name with product trade names.

Who owns MiniMed Group?
Public shareholders own MiniMed Group outright. The company's shares are distributed among investors who participated in the March 2026 IPO and the October 2026 split-off exchange.

Serial biomedical entrepreneur Alfred E. Mann founded MiniMed in 1983 in the Los Angeles area to commercialize the insulin pump. At the time, the only insulin delivery method was repeated daily injections guided by blood draws. MiniMed's early pumps automated basal insulin delivery and established the company as the category's leader, reaching $36 million in sales by 1994 and listing on the Nasdaq under ticker MNMD.

Growth compounded quickly. Revenue climbed from $99.5 million in calendar 1997 to $294 million in calendar 2000, a 43% annual growth rate, as pumps gained acceptance in type 1 diabetes care. In May 2001, Medtronic acquired MiniMed and the affiliated Medical Research Group for roughly $3.7 billion combined, folding the business into its diabetes franchise while keeping the Northridge operations and the MiniMed brand.

Under Medtronic, the product line advanced through successive milestones: the first integrated pump and CGM system in 2006, the first pump that automatically suspended insulin at a preset glucose threshold in 2009, the predictive suspend algorithm in 2015, and the MiniMed 670G in 2017, the world's first hybrid closed-loop system that adjusted basal insulin automatically. The 780G, launched internationally from 2020, added automatic correction boluses and Meal Detection technology. InPen, the smart insulin pen acquired through Companion Medical in 2020, extended the portfolio to injection-based users.

Medtronic announced in May 2025 that it would separate the diabetes business into an independent company within 18 months, arguing that diabetes care runs on a direct-to-consumer commercial model mismatched with Medtronic's hospital-facing core. The new company took the MiniMed name in June 2025. It priced its IPO at $20 per share on March 5, 2026, began trading March 6 on the Nasdaq under MMED, and raised $560 million at a valuation of about $5.35 billion. Medtronic retained roughly 90% at listing.

The final separation completed on October 15, 2026, when Medtronic's exchange offer settled. The offer was oversubscribed 5.4 times, and Medtronic exchanged its entire remaining position, 252.8 million MiniMed shares, for 55.03 million Medtronic ordinary shares. It was the largest split-off ever completed in the medical technology sector.

The diabetes business's regulatory history traveled with it into independence. The MiniMed 600-series pumps carried FDA Class I recalls in 2019 and 2020, including a cybersecurity vulnerability that could have allowed unauthorized remote dosing changes. The Northridge facility received an FDA warning letter in 2021 over complaint-handling and quality system deficiencies while still under Medtronic ownership.

These events drove the quality remediation program that preceded the separation, and MiniMed's filings describe the corrective actions taken before regulatory clearances for newer products resumed. As of November 2026, no new Class I recall has been issued against the company's current pump and sensor line.